Cargando…
Immunotherapy and immunochemotherapy in combating visceral leishmaniasis
Visceral leishmaniasis (VL), a vector-borne disease, is caused by an obligate intramacrophage, kinetoplastid protozoan parasite of the genus Leishmania. Globally, VL is construed of diversity and complexity concerned with high fatality in tropics, subtropics, and Mediterranean regions with ~50,000–9...
Autores principales: | Yadagiri, Ganesh, Singh, Aakriti, Arora, Kanika, Mudavath, Shyam Lal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10229823/ https://www.ncbi.nlm.nih.gov/pubmed/37265481 http://dx.doi.org/10.3389/fmed.2023.1096458 |
Ejemplares similares
-
Modified solid lipid nanoparticles encapsulated with Amphotericin B and Paromomycin: an effective oral combination against experimental murine visceral leishmaniasis
por: Parvez, Shabi, et al.
Publicado: (2020) -
Immunotherapy and Immunochemotherapy in Visceral Leishmaniasis: Promising Treatments for this Neglected Disease
por: Roatt, Bruno Mendes, et al.
Publicado: (2014) -
Characterization and evaluation of amine-modified graphene amphotericin B for the treatment of visceral leishmaniasis: in vivo and in vitro studies
por: Mudavath, Shyam Lal, et al.
Publicado: (2014) -
Sensible graphene oxide differentiates macrophages and Leishmania: a bio-nano interplay in attenuating intracellular parasite
por: Singh, Aakriti, et al.
Publicado: (2020) -
Recuperating Biopharmaceutical Aspects of Amphotericin B and Paromomycin Using a Chitosan Functionalized Nanocarrier via Oral Route for Enhanced Anti-leishmanial Activity
por: Parvez, Shabi, et al.
Publicado: (2020)